It is quite normal to see low titer recombinant protein feedstreams, such as Fc fusion protein, especially during early stage drug research and discovery. To obtain enough purified recombinant proteins, a large volume of feedstream is usually needed.

Magnetic beads are generally effective to purify antibodies at small scale, but there are quite a few scenarios that they become a detriment to your workflow, such as:…

In antibody sequencing, a small quantity of antibodies with decent purity are needed for subsequent processes. Many antibody sequencing companies also need to provide clients at least milligrams of purified antibody along with sequencing reports.…

Purilogics®’ PurexaTM-MQ multimodal anion-exchange chromatography membrane is differentiated by its high binding capacity and effectiveness in removing impurities such as host cell proteins, virus particles, DNA, and aggregates from biologic products under conditions of high solution conductivity…

Purexa™ PrA mini is designed for rapid processing of small quantity of antibodies, especially at low titers. During elution, the first 0.5 mL was discarded. As is shown in the fitures, a majority of the antibody was eluted in the second 0.5 mL elution fraction, which had a concentration of 3.3 mg/mL and was corresponding to a recovery of 78%.

Since interest is growing in the area of virus-like particles (VLPs), we would like to share some notes on what we’ve found in our research, Purilogics would like to highlight a few of our products that are well-suited for purification of VLPs…

Host cell proteins (HCPs) refer to a broad spectrum of proteins produced by the cells in which the product of interest is made. HCPs are process related impurities and are one of many critical quality attributes. Both the FDA and EMA require residual HCP to be reduced to an acceptable level.

RNases are everywhere and are difficult to completely get rid of, however managing RNAse contamination is critical to any setting in which it is paramount to maintain the integrity of RNA.1 There is plenty of instruction on general considerations.

In our second post on monoclonal antibody (mAb) aggregates, we’ve collected some more details about how and under what conditions mAbs may aggregate…

Anion-exchange chromatography (AEX) is based on coulombic interactions between biologics and the purification media.

Vaccines are prophylactics designed to safely introduce epitopes of bacteria or viruses to your immune system to stimulate a response unique to the antigen…

The presence of aggregates in therapeutic monoclonal antibody (mAb) drugs is a major concern because they can decrease product efficacy and cause an immunogenic response in patients…

Purilogics® develops novel membrane adsorbers for biologics purification. Unlike other high capacity membrane products, PurexaTM membrane products are differentiated by their tentacle based ion-exchange ligands.

PurexaTM-DMAE is Purilogics’ line of dimethylaminoethyl-based, weak anion-exchange membrane chromatography products.

It is the highest capacity weak anion-exchange membrane chromatography product line commercially available.

As part of the Small Business Innovative Research (SBIR) program, the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Purilogics with a grant to commercialize affinity membrane adsorbers for purification of influenza vaccines.

If you’re in the custom membrane, filter, or protein purification business or research area, chances are you’re always on the lookout for a better membrane holder to pack your material.

We are excited to attend Bioprocessing Summit from August 13 to August 16, 2019 in Boston, MA. Drs. Graham Temples and Jinxiang Zhou will present latest data for our PurexaTM-MQ and PurexaTM-A chromatographic membrane technologies.

Purilogics, as a pioneer in novel high-performance membrane chromatography development, has received a second Small Business Innovation Research (SBIR) grant from National Institute of General Medical Sciences this year. This new award is a SBIR Phase II grant for ~$1.5 M to develop novel, Protein A based affinity chromatographic membranes with high binding capacities.

Purilogics has been awarded an NIH Small Business Innovation Research (SBIR) Phase I grant for $220,772 to commercialize novel lentiviral vector affinity membrane chromatography technology.

Invited by ITOR/Prisma Healthcare, Purilogics team showcased our Purexa™ membrane chromatography technologies at Discover USC 2019 in Columbia, SC, the third annual university-wide showcase of research, scholarship, leadership and creativity.